Mergers and Acquisitions

Cytena Owners Agree to Sell All Shares to Cellink

August 15, 2019

A strategic agreement has been announced that will see all shares of Cytena be sold to Cellink for a purchase price of EUR30.25 million (US$33.79 million).

ACG Acquires German Pharma Processing Equipment Provider

August 15, 2019

ACG Engineering, which is a part of the ACG Group, has announced its acquisition of a German-based pharma processing equipment provider, Xertecs.

Nemera Acquires Chicago Consulting Firm

August 15, 2019

Nemera has acquired a healthcare focused design and innovation consulting firm in Chicago, IL, Insight Product Development, strengthening its presence in North America.

AskBio Plans to Improve Gene Therapeutics with Synpromics Acquisition

August 13, 2019

AskBio’s acquisition of Synpromics will improve the efficacy of its adeno-associated virus gene therapy vectors.

BioLife Solutions Completes Acquisition of SAVSU Technologies

August 12, 2019

The acquisition strengthens BioLife’s position as a supplier of disruptive, enabling solutions used for manufacturing, storage, and distribution of cell and gene therapies.

Eurofins Genomics Acquires Blue Heron Biotech, Expands Gene Synthesis Capabilities

August 12, 2019

The acquisition expands Eurofins Genomics’ gene portfolio while bolstering Blue Heron’s production capabilities.

Keystone Biologicals Acquired by BioIVT for Portfolio Expansion

August 12, 2019

The acquisition will expand BioIVT’s disease-state portfolio by volume and product range.

Bayer Acquires BlueRock Therapeutics, Boosts Cell Therapy Stake

August 09, 2019

The acquisition will boost Bayer’s cell-therapy development programs, with an initial focus on neurology, cardiology, and immunology.

PTC Therapeutics Acquires Biologics Facility from Bristol-Myers Squibb

August 09, 2019

The facility will support gene therapy production and continued development of PTC’s pipeline of investigational medicines.

Cambrex to be Acquired by Permira Funds

August 07, 2019

An affiliate of the Permira funds has signed an agreement to purchase Cambrex in an approximately $2.4-billion transaction.